Goutham Sunny: NEOPAN – Pancreatic Cancer Update in LAPC
Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, posted on X:
“NEOPAN – Pancreatic Cancer Update In LAPC (locally advanced pancreatic cancer):
Trial compared FOLFIRINOX vs Gemcitabine
- 171 patients, PS ≤1, unresectable cases.
- Primary endpoint: PFS.
- Secondary endpoints: OS, QoL, safety.
Results:
Median PFS:
- FOLFIRINOX: 9.7 months.
- Gemcitabine: 7.7 months.
- HR = 0.7, P = .04.
Median OS:
- FOLFIRINOX: 15.7 months.
- Gemcitabine: 15.4 months.
- HR = 1.02, P = .95.
- Better PFS with FOLFIRINOX
- No OS benefit
- Well tolerated.”
Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Goutham Sunny.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023